Hypoglycaemia Clinical Trial
Official title:
Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients; a Randomized Controlled Trial (RESCUEII)
The purpose of this study is to evaluate the accuracy and reliability of the continuous glucose monitoring system the FreeStyle Navigator® (Abbott, Diabetes Care) in critically ill patients by comparing subcutaneous measuring with the current standard of arterial measuring by a point of care glucometer.
Most patients admitted to the ICU are treated with intensive insulin therapy, according to a
locally developed glucose treatment protocol. The use of a continuous glucose monitoring in
critically ill patients could have the following advantages:
- Better insight in the alterations of the blood glucose levels
- Early detection of hypoglycemia's or hyperglycaemia's, and subsequently more stable
glycemic levels.
- Fewer blood samples
- Decreased workload for the nursing staff
In this study, patients will be randomized in: 1. The Freestyle group or 2. The AccuChek
Group.
Patients in both groups will receive a Freestyle Navigator device, which will stay on the
patient up to 5 days, or until discharge from the ICU.
The medical treatment of both study groups will be equal, except for the frequency of the
glucose level measurements and the resulting adjustments according to the treatment
protocol. In the Freestyle group extra glucose level measurements will be made in response
to alarms from the device.
In both groups, every 4 hours blood glucose values will be obtained using a blood gas
analyzer (BGA). When a control measurement by BGA results in a glucose level of <2.2 or >25
mmol/l, the value will be transmitted to the Patient Data Management System (PDMS) and gives
an alarm. Otherwise, the value will be blinded in the PDMS.
Freestyle Navigator data will be downloaded from the device. Blood glucose values obtained
in the course of usual care will be compared with time-matched Freestyle Navigator values to
assess device accuracy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01922817 -
DPP4inhibitors in Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT02107326 -
Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes
|
N/A | |
Completed |
NCT01337362 -
Recurrent Hypoglycaemia in Type 1 Diabetes
|
N/A | |
Completed |
NCT02341313 -
Point of Care Ketone Measurement in the Newborn
|
||
Completed |
NCT01347801 -
Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1
|
N/A | |
Completed |
NCT05470842 -
How Common is Hypoglycaemia in Older People With Diabetes Who Fall?
|
N/A | |
Completed |
NCT02778269 -
Predicting Hypoglycaemia and Arrhythmias in the Patient With Diabetes and CKD - Validation Study
|
N/A | |
Active, not recruiting |
NCT02241317 -
Diabetes Mellitus at the University Medical Center of Mannheim
|
N/A | |
Completed |
NCT02057848 -
Carbohydrates to Prevent Hypoglycaemia During Physical Activity in Patients With Type 1 Diabetes
|
N/A | |
Terminated |
NCT02836353 -
Metabolic Consequences of Gastrointestinal Surgery
|
N/A | |
Completed |
NCT02347553 -
Effect of Hypoglycaemia on Social Cognition and Cardiac Conduction
|
N/A |